GlaxoSmithKline Pharmaceuticals on Thursday said it has decided to discontinue production and sale of its acidity and heartburn tablet Zinetac in India. The drugmaker was last year contacted by regulatory authorities regarding the detection of cancer-causing substance NDMA in Zinetac. Subsequently, GSK had initiated a voluntary recall of the medicine in September 2019 as a precaution.